StockData
Arvinas, Inc. logo

Arvinas, Inc. (ARVN) stock

ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.82+0.05 (+0.74%)

Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –

Arvinas cash

Cash and short-term investments held at the end of each period.

Arvinas's cash was $567.90M at Jun 30, 2026. For fiscal 2025 it was $685.40M, down 34.1% from the year before. The highest annual figure on record is $1.51B in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$685.40M-34.1%
FY2024Dec 31, 2024$1.04B-17.6%
FY2023Dec 31, 2023$1.26B+4.1%
FY2022Dec 31, 2022$1.21B-19.7%
FY2021Dec 31, 2021$1.51B+118.9%
FY2020Dec 31, 2020$688.60M+145.2%
FY2019Dec 31, 2019$280.86M+49.5%
FY2018Dec 31, 2018$187.84M+379.5%
FY2017Dec 31, 2017$39.17M+669.8%
FY2016Dec 31, 2016$5.09M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$567.90M-34.1%
Q1 FY2026Mar 31, 2026$614.90M-35.6%
Q4 FY2025Dec 31, 2025$685.40M-34.1%
Q3 FY2025Sep 30, 2025$787.60M-29.8%
Q2 FY2025Jun 30, 2025$861.20M-29.9%
Q1 FY2025Mar 31, 2025$954.30M-18.4%
Q4 FY2024Dec 31, 2024$1.04B-17.6%
Q3 FY2024Sep 30, 2024$1.12B+12.3%
Q2 FY2024Jun 30, 2024$1.23B+18.3%
Q1 FY2024Mar 31, 2024$1.17B+4.1%
Q4 FY2023Dec 31, 2023$1.26B+4.1%
Q3 FY2023Sep 30, 2023$998.50M-21.4%
Q2 FY2023Jun 30, 2023$1.04B-22.7%
Q1 FY2023Mar 31, 2023$1.12B-21.3%
Q4 FY2022Dec 31, 2022$1.21B-19.7%
Q3 FY2022Sep 30, 2022$1.27B-18.0%
Q2 FY2022Jun 30, 2022$1.34B+122.0%
Q1 FY2022Mar 31, 2022$1.43B+119.3%
Q4 FY2021Dec 31, 2021$1.51B+118.9%
Q3 FY2021Sep 30, 2021$1.55B+523.2%
Q2 FY2021Jun 30, 2021$605.05M+149.3%
Q1 FY2021Mar 31, 2021$651.30M+147.8%
Q4 FY2020Dec 31, 2020$688.60M+145.2%
Q3 FY2020Sep 30, 2020$248.56M+30.5%
Q2 FY2020Jun 30, 2020$242.70M+52.5%
Q1 FY2020Mar 31, 2020$262.83M+50.2%
Q4 FY2019Dec 31, 2019$280.86M+49.5%
Q3 FY2019Sep 30, 2019$190.51M+112.2%
Q2 FY2019Jun 30, 2019$159.17M+4647.8%
Q1 FY2019Mar 31, 2019$174.96M+187.6%
Q4 FY2018Dec 31, 2018$187.84M+379.5%
Q3 FY2018Sep 30, 2018$89.79M+3554.6%
Q2 FY2018Jun 30, 2018$3.35M-34.1%
Q1 FY2018Mar 31, 2018$60.83M–
Q4 FY2017Dec 31, 2017$39.17M–
Q3 FY2017Sep 30, 2017$2.46M–
Q4 FY2016Dec 31, 2016$5.09M–

More Arvinas figures

See a number that looks wrong?